ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The holding company Innoviva has agreed to buy Entasis Therapeutics in a deal that values the antibiotic developer at $113 million. Innoviva already owns about 60% of Entasis’s stock. Entasis is a 2015 spin-off from AstraZeneca that has a pipeline of drug candidates for multidrug-resistant gram-negative bacteria. It plans to submit a new drug application for its lead drug, sulbactam-durlobactam, later this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X